The Anti-Diabetic Drug Metformin Suppresses Pathological Retinal Angiogenesis via Blocking the mTORC1 Signaling Pathway in Mice (Metformin Suppresses Pathological Angiogenesis)

References

• Feldman-Billard S, Dupas B. Eye disorders other than diabetic retinopathy in patients with diabetes. Diabetes Metab. 2021;47(6):101279. doi: 10.1016/j.diabet.2021.101279.
   PubMed Web of Science ®Google Scholar
• Hsu SK, Cheng KC, Mgbeahuruike MO, Lin YH, Wu CY, Wang HD, Yen CH, Chiu CC, Sheu SJ. New insight into the effects of metformin on diabetic retinopathy, aging and cancer: nonapoptotic cell death, immunosuppression, and effects beyond the AMPK pathway. Int J Mol Sci. 2021;22(17):9453. doi: 10.3390/ijms22179453.
   PubMed Web of Science ®Google Scholar
• Amin SV, Khanna S, Parvar SP, Shaw LT, Dao D, Hariprasad SM, Skondra D. Metformin and retinal diseases in preclinical and clinical studies: insights and review of literature. Exp Biol Med. 2022;247(4):317–329. doi: 10.1177/15353702211069986.
   Web of Science ®Google Scholar
• Han J, Li Y, Liu X, Zhou T, Sun H, Edwards P, Gao H, Yu FS, Qiao X. Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS One. 2018;13(3):e0193031. doi: 10.1371/journal.pone.0193031.
   PubMed Web of Science ®Google Scholar
• Li Y, Gappy S, Liu X, Sassalos T, Zhou T, Hsu A, Zhang A, Edwards PA, Gao H, Qiao X. Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium. PLoS One. 2022;17(7):e0268451. doi: 10.1371/journal.pone.0268451.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim M, Choi MY, Lee DH, Roh GS, Kim HJ, Kang SS, Cho GJ, Kim SJ, Yoo JM, et al. Metformin protects against retinal cell death in diabetic mice. Biochem Biophys Res Commun. 2017;492(3):397–403. doi: 10.1016/j.bbrc.2017.08.087.
   PubMed Web of Science ®Google Scholar
• Nahar N, Mohamed S, Mustapha NM, Lau S, Ishak NIM, Umran NS. Metformin attenuated histopathological ocular deteriorations in a streptozotocin-induced hyperglycemic rat model. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(3):457–467. doi: 10.1007/s00210-020-01989-w.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Asano D, Ushikubo H, Morita A, Mori A, Sakamoto K, Ishii K, Nakahara T. Metformin protects against NMDA-induced retinal injury through the MEK/ERK signaling pathway in rats. Int J Mol Sci. 2021;22(9):4439. doi: 10.3390/ijms22094439.
   PubMed Web of Science ®Google Scholar
• Zhang K, Wang T, Sun GF, Xiao JX, Jiang LP, Tou FF, Qu XH, Han XJ. Metformin protects against retinal ischemia/reperfusion injury through AMPK-mediated mitochondrial fusion. Free Radic Biol Med. 2023;205:47–61. doi: 10.1016/j.freeradbiomed.2023.05.019.
   PubMed Web of Science ®Google Scholar
• Esfahanian N, Shakiba Y, Nikbin B, Soraya H, Maleki-Dizaji N, Ghazi-Khansari M, Garjani A. Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells. Mol Med Rep. 2012;5(4):1068–1074. doi: 10.3892/mmr.2012.753.
   PubMed Web of Science ®Google Scholar
• Soraya H, Esfahanian N, Shakiba Y, Ghazi-Khansari M, Nikbin B, Hafezzadeh H, Maleki Dizaji N, Garjani A. Anti-angiogenic effects of metformin, an AMPK activator, on human umbilical vein endothelial cells and on granulation tissue in rat. Iran J Basic Med Sci. 2012;15(6):1202–1209.
   PubMed Web of Science ®Google Scholar
• Joe SG, Yoon YH, Choi JA, Koh JY. Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1. PLoS One. 2015;10(3):e0119708. eCollection 2015. doi: 10.1371/journal.pone.0119708.
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. doi: 10.1007/s00125-017-4342-z.
   PubMed Web of Science ®Google Scholar
• Chomanicova N, Gazova A, Adamickova A, Valaskova S, Kyselovic J. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin. Physiol Res. 2021;70(4):501–508. doi: 10.33549/physiolres.934618.
   PubMed Web of Science ®Google Scholar
• Yagasaki R, Nakahara T, Mori A, Sakamoto K, Ishii K. Effects of mTOR inhibition on normal retinal vascular development in the mouse. Exp Eye Res. 2014;129:127–134. doi: 10.1016/j.exer.2014.11.005.
   PubMed Web of Science ®Google Scholar
• Yagasaki R, Nakahara T, Ushikubo H, Mori A, Sakamoto K, Ishii K. Anti-angiogenic effects of mammalian target of rapamycin inhibitors in a mouse model of oxygen-induced retinopathy. Biol Pharm Bull. 2014;37(11):1838–1842. doi: 10.1248/bpb.b14-00487.
   PubMed Web of Science ®Google Scholar
• Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, Hoxhaj G, Saghatelian A, Shaw RJ, Manning BD. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25(2):463–471. doi: 10.1016/j.cmet.2016.12.009.
   PubMed Web of Science ®Google Scholar
• Xu L, Kong L, Wang J, Ash JD. Stimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2018;115(41):10475–10480. doi: 10.1073/pnas.1802724115.
   PubMed Web of Science ®Google Scholar
• Morita A, Yoshizumi M, Arima S, Mori A, Sakamoto K, Nagamitsu T, Nakahara T. Pharmacological depletion of retinal neurons prevents vertical angiogenic sprouting without affecting the superficial vascular plexus. Dev Dyn. 2021;250(4):497–512. doi: 10.1002/dvdy.263.
   PubMed Web of Science ®Google Scholar
• Hayashi I, Aoki Y, Ushikubo H, Asano D, Mori A, Sakamoto K, Nakahara T, Ishii K. Protective effects of PF-4708671 against N-methyl-d-aspartic acid-induced retinal damage in rats. Fundam Clin Pharmacol. 2016;30(6):529–536. doi: 10.1111/fcp.12216.
   PubMed Web of Science ®Google Scholar
• Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016–1023. doi: 10.1038/ncb2329.
   PubMed Web of Science ®Google Scholar
• Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92(3):905–909. doi: 10.1073/pnas.92.3.905.
   PubMed Web of Science ®Google Scholar
• Tadakawa M, Takeda T, Li B, Tsuiji K, Yaegashi N. The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling pathway in ELT-3 cells. Mol Cell Endocrinol. 2015;399:1–8. doi: 10.1016/j.mce.2014.08.012.
   PubMed Web of Science ®Google Scholar
• Qu H, Yang X. Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells. Cell Biochem Biophys. 2015;71(2):931–936. doi: 10.1007/s12013-014-0287-8.
   PubMed Web of Science ®Google Scholar
• Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer. 2009;100(6):971–978. doi: 10.1038/sj.bjc.6604921.
   PubMed Web of Science ®Google Scholar